Lenz Therapeutics, Inc. · NASDAQ:LENZ
Lenz Therapeutics — Q2 2026 Earnings Presentation
7 slides from Lenz Therapeutics's earnings presentation, Aug 11, 2026
Slide 1: LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 11, 2026 LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasi
Slide 2: Broad uptake by eye care professionals
Broad uptake by eye care professionals (“ECPs”), with over 13,000 unique prescribers from launch through Q2 2026, with approximately 75% prescribing multiple times. In July 2026, launched a telehealth prescribing option to accelerate patient access to VIZZ, offering patients the convenience of an in
Slide 3: Cash Position
Cash Position: Cash, cash equivalents and marketable securities were $220.0 million as of June 30, 2026. Product Sales, net: Product sales, net was $1.7 million and $3.4 million for the three and six months ended June 30, 2026, respectively, driven by approximately 27,000 and 52,000 packs sold and d
Slide 4: About Presbyopia
website for 30 days following the event. About Presbyopia Presbyopia is the inevitable loss of near vision associated with aging, impacting the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change sha
Slide 5: Adverse Reactions
ADVERSE REACTIONS The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions
Slide 6: Contact
Contact: Dan Chevallard LENZ Therapeutics IR@LENZ-Tx.com LENZ Therapeutics, Inc. Selected Balance Sheet Highlights (in thousands) December 31, June 30, 2026 2025 (unaudited) Cash and cash equivalents $ 24,208 $ 25,179 Marketable securities 195,795 267,168 Total assets 236,596 305,876 Total liabiliti
Slide 7: Net loss before income taxes
Net loss before income taxes (31,915 ) (14,412 ) (73,403 ) (29,031) Income tax expense 3 500 3 500 Net loss $ (31,918) $ (14,912) $ (73,406) $ (29,531) Other comprehensive loss: Unrealized loss on marketable securities (179) (85) (871) (158) Comprehensive loss $ (32,097) $ (14,997) $ (74,277) $ (29,